Off-label uses of botulinum toxin A in chronic itch-related dermatological disorders: a retrospective study

Manila Purushottama; Chaithra Shenoy; Oliver C. Lobo; B. S. Chandrashekar

doi:10.18203/2320-1770.ijrcog20262108

Authors

Manila Purushottama Department of Aesthetic Dermatology, CUTIS Academy of Cutaneous Sciences, Vijayanagar, Bangalore, Karnataka, India
Chaithra Shenoy Department of Aesthetic Dermatology, CUTIS Academy of Cutaneous Sciences, Vijayanagar, Bangalore, Karnataka, India
Oliver C. Lobo Department of Aesthetic Dermatology, CUTIS Academy of Cutaneous Sciences, Vijayanagar, Bangalore, Karnataka, India
B. S. Chandrashekar Department of Aesthetic Dermatology, CUTIS Academy of Cutaneous Sciences, Vijayanagar, Bangalore, Karnataka, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20262108

Keywords:

Botulinum toxin, Pruritus vulvae, Chronic itch

Abstract

Background: Botulinum neurotoxin (BONT) produced by anaerobic clostridium botulinum exerts diverse biological effects by acting on various neurotransmitters like acetylcholine, substance P, glutamate, mast cell, calcitonin gene related peptide (CGRP). Initially linked with aesthetic dermatology, it is now explored in various dermatological conditions including rosacea, post-herpetic neuralgia, keloid and hypertrophic scars and itch related disorders. The aim to investigate the diverse dermatological applications of BONT A in chronic itch disorders and evaluate its therapeutic outcomes in a retrospective study.

Methods: A retrospective, single centre study was conducted from December 2018 to December 2023. Information of all patients who underwent intradermal botulinum toxin injections for chronic itch-related disorders was extracted from the database. Information including demographic profiles, diagnosis, previous medications, the dosage of toxin administered, duration of symptomatic relief and post-procedure complications were recorded. Treatment efficacy was assessed based on the patient reported improvement: mild (1-24%), moderate (25-49%, good (50-75%) and excellent (>76% improvement).

Result: A total of 33 patients (22 female and 11 male) were enrolled with diagnoses such as pruritus vulvae, scrotal dysesthesia, post-herpetic neuralgia, notalgia paresthetica, lichen simplex chronicus, and burning foot syndrome. Toxin was injected as 1 unit/cm² and total number of toxins administered depended on the area involved. Majority of patients reported good improvement (50-75%) in itching lasting for 3-5 months.

Conclusion: Intradermal BONT A injection showed promising long-lasting results in managing chronic itch related disorders which do not respond to conventional modalities of treatment.

References

Al-Ghamdi AS, Alghanemy N, Joharji H, Al-Qahtani D, Alghamdi H. Botulinum toxin: Non cosmetic and off-label dermatological use. J Dermatolo Dermatol Surg. 2015;19:1-8.

Nigam PK, Nigam A. Botulinum toxin. Indian J Dermatol. 2010;55(1):8-10.

Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo-controlled trial. BMJ. 2001;323(7313):596-9.

Järvikallio A, Harvima IT, Naukkarinen A. Mast cells, nerves and neuropeptides in atopic dermatitis and nummular eczema. Arch Dermatol Res. 2003;295(1):2-7.

Wilson SR, Nelson AM, Batia L, Morita T, Estandian D, Owens DM, et al. The ion channel TRPA1 is required for chronic itch. J Neurosci. 2013;33:9283-94.

Gazerani P. How Does Botulinum Toxin Inhibit Itch? Toxins (Basel). 2022;14(10):701.

Kim YS, Hong ES, Kim HS. Botulinum Toxin in the Field of Dermatology: Novel Indications. Toxins (Basel). 2017;9(12):403.

Jeffry J, Kim S, Chen ZF. Itch signaling in the nervous system. Physiology (Bethesda). 2011;26(4):286-92.

Nattkemper LA, Vander AD, Stull CM, Lavery M, Rodriguez RV, McGregory M, et al. Prolonged Antipruritic Effect of Botulinum Toxin Type A on Cowhage-induced Itch: A Randomized, Single-blind, Placebo-controlled Trial. Acta Dermatol Venereol. 2023103:adv6581.

Weinfeld PK. Successful treatment of notalgia paresthetica with botulinum toxin type A. Arch Dermatol. 2007;143(8):980-2.

Pérez-Pérez L, García-Gavín J, Allegue F, Caeiro JL, Fabeiro JM, Zulaica A. Notalgia paresthetica: treatment using intradermal botulinum toxin A. Actas Dermosifiliogr. 2014;105(1):74-7.

Ri S, Kivi A, Wissel J. The Safety and Effect of Local Botulinumtoxin A Injections for Long-Term Management of Chronic Pain in Post-Herpetic Neuralgia: Literature Review and Cases Report Treated with Incobotulinumtoxin A. J Pers Med. 2021;11:758.

Heckmann M, Heyer G, Brunner B, Plewig G. Botulinum toxin type A injection in the treatment of lichen simplex: An open pilot study. J Am Acad Dermatol. 200;46(4):617-9.

Raef HS, Elmariah SB. Vulvar Pruritus: A Review of Clinical Associations, Pathophysiology and Therapeutic Management. Front Med (Lausanne). 2021;8:649402.

Rodríguez-Cerdeira C, Guerra-Tapia A, Bravo G, Álvarez MJ, Pérez-Villaverde P. Vulvar dysesthesia: New treatments for a real therapeutic challenge. Open Dermatol J. 2008;2(1).

Raef HS, Elmariah SB. Treatment of male genital dysesthesia with botulinum toxin. JAAD Case Rep. 2021;10:60-2.

Shin MC, Wakita M, Xie DJ, Yamaga T, Iwata S, Torii Y, et al. Inhibition of membrane Na+ channels by A type botulinum toxin at femtomolar concentrations in central and peripheral neurons. J Pharmacol Sci. 2012;118(1):33-42.

Wang C, Zhang Q, Wang R, Xu L. Botulinum toxin type A for diabetic peripheral neuropathy pain: a systematic review and meta-analysis. J Pain Res. 2021:3855-63.

Taheri M, Sedaghat M, Solhpour A, Rostami P, Safarpour Lima B. The Effect of Intradermal Botulinum Toxin a injections on painful diabetic polyneuropathy. Diabetes Metab Syndr. 2020;14(6):1823-8.